Regulation of Cognitive Enhancement Biotechnology in China

1. Introduction

Cognitive enhancement biotechnology refers to scientific and technological interventions intended to improve memory, attention, learning capacity, alertness, decision-making, or other aspects of human cognition beyond ordinary therapeutic needs. It includes brain-computer interfaces (BCIs), neurostimulation, cognitive-enhancing drugs, genetic interventions, and emerging neurotechnologies.

In China, cognitive enhancement biotechnology is not governed by one comprehensive statute. Instead, its regulation is distributed across drug and medical-device legislation, human biomedical research rules, biotechnology ethics requirements, personal information protection law, and national biosecurity legislation.

A key legal distinction is between therapeutic treatment and non-therapeutic enhancement. A technology developed to restore memory after neurological injury may be assessed differently from an intervention intended to increase the memory capacity of a healthy person. The applicable requirements depend on the technology, its intended use, the research setting, and the risks involved.

China's regulatory framework seeks to address patient safety, scientific integrity, informed consent, human dignity, protection of biological information, and risks arising from the misuse of biotechnology.

2. Principal Legal Framework

A. Drug Administration Law of the People's Republic of China

China's Drug Administration Law, revised in 2019, regulates the development, clinical testing, registration, manufacture, and marketing of pharmaceutical products.

Cognitive-enhancing drugs intended for clinical use may fall within this framework. A drug claiming to improve memory, concentration, or learning must satisfy applicable requirements concerning safety, efficacy, quality, and registration.

The law does not create a general entitlement to market a substance merely because it is described as a cognitive enhancer. Where clinical trials are required, the sponsor must comply with the relevant regulatory approval and clinical research requirements.

Legal significance: A pharmaceutical product intended to enhance cognition cannot lawfully bypass applicable drug registration and safety controls simply by being marketed as a lifestyle or performance-enhancement product.

B. Regulations on the Administration of Medical Institutions and Medical Device Regulation

Brain-computer interfaces, neurostimulation equipment, and implanted neural devices may be subject to China's medical-device regulatory system when they fall within the legal definition of a medical device.

The Medical Device Regulation, revised in 2021, establishes requirements for classification, registration or filing, clinical evaluation, production, and post-market supervision.

A device used to restore communication or movement in a patient may have a different intended purpose and risk classification from a device designed to alter the cognition of a healthy individual. Its classification must be determined under the applicable regulatory rules rather than assumed from the technology's name.

Legal significance: Cognitive enhancement devices cannot avoid medical-device regulation where their actual intended use brings them within the statutory framework.

3. Ethics Guidelines for Brain-Computer Interface Research, 2024

China's Ethics Guidelines for Brain-Computer Interface Research, published in February 2024, are particularly important for cognitive enhancement biotechnology. The guidelines distinguish between restorative technology and enhancement technology, and emphasize that BCI research should principally serve human health and well-being.

Ministry of Science and Technology

+1

The guidelines identify several important safeguards:

Risk assessment: Researchers must assess potential harm associated with brain-signal collection, stimulation, implantation, and long-term device use.

Ethics review: Research involving human participants must undergo the applicable ethics review.

Informed consent: Participants must receive adequate information about foreseeable risks and benefits.

Safety verification: Relevant safety and effectiveness evidence, including biocompatibility testing and appropriate animal studies, must be provided for invasive systems.

Limits on enhancement: Researchers should exercise restraint when developing technology that enhances the abilities of healthy people.

The guidelines also caution against addiction, disruption of normal thought and behaviour, and technologies that weaken human autonomy or interfere with independent decision-making.

Center for Security and Emerging Technology

+1

An important legal qualification is that these guidelines are principally ethical guidance rather than a standalone statute creating a universal criminal prohibition on cognitive enhancement. Binding statutory and regulatory requirements continue to apply independently.

4. Human Research Ethics Review Measures, 2023

The Measures for Ethical Review of Life Science and Medical Research Involving Humans, issued in February 2023, provide a central framework for research involving human participants, biological samples, and personal information.

Under this framework, institutions must arrange appropriate ethics review for covered research. Reviewers consider scientific validity, risk-benefit balance, participant selection, consent procedures, privacy protection, and the safeguards required to protect human dignity.

ncmhc.org.cn

+1

For cognitive enhancement research, this means that an experiment involving neurostimulation, an investigational cognitive drug, or an invasive brain implant cannot rely solely on the researcher's belief that the technology will improve performance.

Where an intervention presents substantial neurological risks without a sufficient medical benefit, the ethics committee may determine that the proposed study is unacceptable.

The Interim Measures for Scientific and Technological Ethical Review, effective from 1 December 2023, also identify invasive BCI clinical research for neurological or psychiatric treatment and certain human-machine integration systems affecting behaviour, emotions, and health as activities requiring particular ethical scrutiny, including review or re-review where specified.

Ministry of Science and Technology

+1

5. Regulation of Genetic Cognitive Enhancement

Genetic enhancement raises more serious concerns because genetic interventions may create irreversible or heritable consequences.

China's regulatory framework includes the Biosecurity Law, human genetic resources regulations, and rules governing human biomedical research and reproductive medicine. Genetic research involving human participants must comply with the applicable consent, ethics, and regulatory requirements.

Particularly sensitive are interventions that alter human embryos or reproductive cells. Such activities cannot be treated as ordinary cognitive enhancement experiments merely because researchers claim that the intervention could improve intelligence, memory, or learning.

The legal position must distinguish between permitted basic research, regulated clinical research, and prohibited or otherwise unlawful reproductive applications. The precise restriction depends on the intervention and the applicable rule.

6. Important Case Law

A. He Jiankui Human Gene-Editing Case (2019)

The most significant Chinese judicial precedent relevant by analogy is the case against He Jiankui and his collaborators.

In December 2019, the Shenzhen Nanshan District People's Court convicted He of illegal medical practice in connection with unauthorized human embryo gene-editing experiments. He received three years' imprisonment and a fine of RMB 3 million. Two collaborators also received criminal sentences. The experiments resulted in the birth of three genetically edited children.

Supreme People's Court

Legal principle: Scientific innovation does not excuse violations of medical regulations, falsification of ethics-review documents, or disregard of safety requirements.

Relevance to cognitive enhancement: Although the case concerned genetic editing intended to confer resistance to HIV rather than improve cognition, it demonstrates the potential criminal consequences of unauthorized human genetic interventions. A comparable cognitive enhancement experiment involving embryos could raise similar issues if it violated applicable legal requirements.

B. Direct Cognitive Enhancement Case Law

The identified Chinese sources do not establish a reported judicial decision specifically prohibiting cognitive enhancement through BCI technology in healthy adults.

Accordingly, it would be inaccurate to present the He Jiankui judgment as a direct precedent on neural enhancement. It is an analogous authority demonstrating how Chinese courts may respond to serious violations of biotechnology and medical regulation.

7. Data Protection and Individual Autonomy

Cognitive enhancement systems may collect neural signals, behavioural patterns, attention measurements, or information from which mental states can be inferred.

Where such information constitutes personal information, the Personal Information Protection Law may apply. Sensitive personal information receives heightened protection, and processing must satisfy the relevant legal conditions and safeguards.

Neural data also raise questions about whether employers, educational institutions, insurers, or technology companies could use cognitive measurements to discriminate against individuals. Such uses must be assessed under applicable privacy, employment, consumer-protection, and other relevant laws.

8. Conclusion

China regulates cognitive enhancement biotechnology through a combination of medical regulation, human research ethics, genetic governance, biosecurity, and personal information protection.

The 2024 BCI ethics guidelines are especially important because they expressly distinguish enhancement of healthy individuals from restoration of impaired functions. However, China does not impose one blanket statutory ban on every form of cognitive enhancement. The legality of a particular intervention depends on its design, intended purpose, risk profile, and applicable regulatory requirements.

The He Jiankui case illustrates the possible criminal consequences of serious violations in human biotechnology, while the 2023 ethics review measures and 2024 BCI guidelines establish safeguards relevant to future cognitive enhancement research.